Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Modern Molecular Taxonomy01:29

Modern Molecular Taxonomy

69
Advancements in molecular biology have revolutionized the identification and characterization of bacteria, with multiple methods leveraging DNA sequencing for enhanced precision. As sequencing technologies improve and costs decline, these approaches are increasingly used in clinical, environmental, and evolutionary studies.Multilocus Sequence Typing (MLST) examines several housekeeping genes, essential chromosomal genes encoding cellular functions, to distinguish strains. Approximately...
69
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Applications of Molecular Taxonomy01:20

Applications of Molecular Taxonomy

51
Molecular taxonomy has revolutionized the understanding and classification of bacteria, providing precise insights into their diversity, evolutionary relationships, and ecological roles. By utilizing molecular techniques such as DNA sequencing and fingerprinting, researchers have made significant strides in various fields related to bacterial studies.Resolving Taxonomic AmbiguitiesMolecular taxonomy has been instrumental in distinguishing closely related bacterial species initially thought to...
51
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

204
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
204

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

"Better Safe Than Sorry?": Reconsidering ADAMTS13 Testing and Plasma Exchange for Suspected aTTP as a High‑Value Care Priority.

American journal of medical quality : the official journal of the American College of Medical Quality·2026
Same author

Saliva and blood miRNAs as complementary biomarkers for esophageal cancer detection.

Frontiers in oncology·2026
Same author

Diagnostic value of integrating salivary and blood miRNAs for pancreatic cancer detection.

Frontiers in oncology·2025
Same author

Cell-free HPV-DNA as a high-accuracy biomarker for treatment de-escalation in HPV-positive head and neck squamous cell carcinoma.

Frontiers in oncology·2025
Same author

Circulating miRNAs as liquid biopsy biomarkers for diagnosis in patients with colorectal cancer: a systematic review and meta-analysis.

Frontiers in genetics·2025
Same author

Global prevalence and risk factors of suicidality among head and neck cancer patients-systematic review and meta-analysis.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2025

Related Experiment Video

Updated: Aug 9, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.4K

Molecular classification and therapeutics in diffuse large B-cell lymphoma.

Gaelen Shimkus1, Taichiro Nonaka2,3

  • 1School of Medicine, Louisiana State University Health Shreveport, Shreveport, LA, United States.

Frontiers in Molecular Biosciences
|February 23, 2023
PubMed
Summary

New genetic subgroups for diffuse large B-cell lymphoma (DLBCL) offer improved prognostication and personalized treatment strategies. Identifying these DLBCL subtypes can guide targeted therapies for better patient outcomes.

Keywords:
DLBCLmolecular classificationmolecular diagnosticssignaling pathwaytargeted therapy

More Related Videos

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

26.8K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

13.8K

Related Experiment Videos

Last Updated: Aug 9, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.4K
VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

26.8K
From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

13.8K

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Current immunohistochemical methods for Diffuse Large B-cell Lymphoma (DLBCL) lack prognostic value and do not guide treatment adjustments.
  • Standardized treatment regimens for refractory DLBCL offer no individualization based on patient genotype.
  • The addition of rituximab to CHOP therapy represents the only significant recent advancement in DLBCL treatment.

Purpose of the Study:

  • To explore novel strategies for categorizing DLBCL based on genetic abnormalities.
  • To predict disease course more accurately by identifying genetic subgroups.
  • To enable the development of targeted treatment strategies for specific DLBCL molecular subtypes.

Main Methods:

  • Utilizing novel algorithms and next-generation sequencing (NGS) techniques.
  • Identifying recurrent genetic alterations and pathway dysregulations within DLBCL.
  • Analyzing potential therapeutic targets within identified genetic subgroups.

Main Results:

  • Identification of 4 to 7 distinct DLBCL subgroups based on genetic profiles.
  • Discovery of potentially significant and actionable genetic alterations within these subgroups.
  • Demonstration of promising therapeutic potential for drugs targeting specific pathways (e.g., BCR signaling, NF-κB, epigenetic regulation) in recurrent DLBCL.

Conclusions:

  • Genetic subtyping of DLBCL offers a more precise approach to prognostication compared to traditional methods.
  • Targeted therapies directed at specific molecular pathways show promise for recurrent DLBCL.
  • Implementation of genetic subgroups is crucial for data collection to validate significance and guide future treatment decisions.